



G Protein Coupled Receptors Potentially Involved in Oligodendrogenesis: A Gene Expression Analysis

Neda Karami^{1,2}, Hadi Aligholi³, Moosa Rahimi⁴, Hassan Azari⁵, *Tahereh Kalantari^{1,2}

1. Division of Medical Biotechnology, Department of Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
2. Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
3. Department of Neuroscience, School of Advanced Medical Sciences and Technology, Shiraz University of Medical Sciences, Shiraz, Iran
4. Laboratory of Basic Sciences, Mohammad Rasul Allah Research Tower, Shiraz University of Medical Sciences, Shiraz, Iran
5. Neural Stem Cell Laboratory, Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, FL, United States

*Corresponding Author: Email: Kalantari_t@sums.ac.ir

(Received 10 Apr 2021; accepted 19 Jul 2021)

Abstract

Background: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system characterized by infiltration of inflammatory leukocytes to the CNS followed by oligodendrocyte cell death, myelin sheath destruction, and axonal injury. A logical incidence occurring after demyelination is remyelination. G-protein coupled receptors (GPCRs) activate internal signal transduction cascades through binding to different ligands. This family of receptors are targeted by more than 40% of currently marketed drugs. GPCRs can be successfully targeted for induction of remyelination. GPCRs highly enriched in oligodendrocyte progenitor cells compared to oligodendrocytes are proposed to hamper oligodendrocyte differentiation and therefore their inhibition might induce remyelination. This study aimed to investigate the expression of GPCRs in silico and in vitro.

Methods: We performed gene expression analysis using DAVID and Panther websites on a RNA-seq dataset (GSE52564 accession number). Primary embryonic neural stem/progenitor cell isolation and culture were performed and subsequently NSPCs were characterized by Immunocytochemistry with Anti-Nestin antibody. Expression of *GPR37L1*, *EDNRB*, *PDGFRA*, *CNPase* and *GFAP* were assessed using real-time PCR. All the experiments were conducted at Shiraz University of Medical Sciences (SUMS), Shiraz, Iran, in the year 2018.

Results: The 14 most highly expressed GPCRs in oligodendrocyte progenitor cells (OPCs) compared to Oligodendrocytes were presented in our study.

Conclusion: The investigation of the most highly expressed GPCRs in OPCs compared to oligodendrocyte in silico and in vitro presents the significant role of GPCRs in remyelination induction. Among the 14 GPCRs mentioned in this study, GPR37L1 is a potential remyelinating drug target and is suggested for further studies.

Keywords: Oligodendrocyte progenitor cells (OPCs); Oligodendrocytes; Remyelination; Demyelination; Gene expression analysis



Introduction

Oligodendrocytes are cells that make and sustain the lipid-rich myelin sheaths insulating and wrapping axons. During development, these cells arise from oligodendrocyte progenitor cells (OPCs) and neural stem cells (NSCs). In the Central Nervous System (CNS) an insult directed at the oligodendrocytes is the most preliminary cause of demyelination. Demyelination is a condition in which concentric layers of compact myelin, surrounding axons are lost (1). Defects in both oligodendrocyte development and demyelination cause various neurological disorders, such as spinal cord injury and multiple sclerosis (MS) (2, 3). A logical corollary to CNS demyelination is frequently the robust regenerative process of remyelination. The source of remyelination is provided by newly formed oligodendrocytes in adult brain through differentiation of Neural stem/progenitor cells (NSPCs) or OPCs (4).

Switching from OPCs differentiation to oligodendrocytes is mostly halted by various factors in different diseases. To overcome this incident and awaken the sequestered reservoir of remyelination, pharmacological activation of these cells has recently become the center of attention (5). There is the possibility of re-purposing the currently marketed drugs for remyelination. G-protein-coupled receptors (GPCRs) trigger one of the most common response pathways in the cell formed by the guanine nucleotide-binding proteins (G proteins). Approximately half of all drugs currently on the market target these receptors (6). Hunting for new drug targets can be tedious and costly through functional screening of drugs in 2D cell cultures for remyelination. A study published in Nature shed light on the efficacy of two drugs, miconazole and clobetasol in promoting precocious myelination in vivo in early postnatal mouse pups (7). A study discovered Benzotropine (a well-established approved drug for the treatment of Parkinson's disease) to be the most effective inducer of OPC differentia-

tion (8). The targets for these proposed drugs are mostly GPCRs.

Rational screening of drug targets using in silico tools is another faster and less costly way for drug target discovery. Studies for functional rational drug/drug target screening for remyelination were lacking. In the current study, we evaluated differential GPCRs expression in oligodendrocytes and OPCs to rationally propose drug targets for remyelination. In an RNA-seq data analysis using panther and David websites in the current study, we investigated the expression level of GPR37L1 a closely related orphan GPCR to GPR37 (9-11). In addition, we derived the most expressed GPCRs in oligodendrocyte progenitor cells compared to mature oligodendrocytes. Several of the found GPCRs have already been linked to remyelination induction. Among the GPCRS, GPR37L1 is a potential drug target for remyelination induction. GPR37L1 is a constitutive expressed orphan GPCR with a distinct expression pattern in glial cells and CNS. The paucity of information on this receptor has cast a shadow over its possible fascinating role in myelination. We proposed GPR37L1 and other mentioned GPCRs as drug targets for remyelination induction and promotion of oligodendrocyte differentiation.

Materials and Methods

Gene Set Enrichment and pathway Analysis

RNA-seq data was downloaded from the website (https://web.stanford.edu/group/barres_lab/bra_in_rnaseq.html). The accession number from GEO datasets was GSE52564. The data sets were analyzed using DAVID and Panther websites. First, the differential gene analysis following annotation of RNA-seq data were performed. Next, we did a gene set enrichment analysis displaying different gene sets (such as GPCRs and lipid biosynthesis gene sets) upregulated in OPCs and OLs. Finally, we derived the pathway analysis in

both cell types and compared the expression of highly expressed pathways in each cell type.

All these were done according to the published protocols of each website in the journal of Nature protocols (9, 10). All the experiments were conducted at Shiraz University of Medical Sciences (SUMS), Shiraz, Iran, in the year 2018. Animals, Surgery and Dissection of mice cortices All mice examined in this study were obtained from Comparative and Experimental Medical Center of Shiraz University of Medical Sciences (SUMS). All animal procedures were conducted following protocols approved by the Animal Ethics and welfare committee of SUMS (no. IR.SUMS.REC.1396.S448). Female and male BALB/c mice were mated at 1:2 ratio (male: female) and female mice were checked for the following next 5 d until vaginal plaque was observed.

On the 14th day of the mouse pregnancy, pregnant female mouse was deeply anesthetized with ketamine and xylazine and sacrificed. 14.5 d old mice embryos' heads were dissected with fine scissors to be used further for isolation of NSCs. The cortex was subtly dissected with fine forceps and scissors under dissecting microscope and placed in ice-cold Phosphate Buffered Saline (PBS) solution containing 10% penicillin-streptomycin (Penstrep).

Primary embryonic neural stem cell Isolation and Culture

Following the dissection procedures described above, we pipetted the cell pellet in 1 ml warm Neurocult proliferation medium and counted the number of viable cells using trypan blue 0.4% dead cell exclusion method(12). 2×10^5 viable cells per 1 ml of complete neural stem cell culture medium are cultured in T25 flasks (SPL). For a T25 Flask we cultured the cells with complete medium containing Neurocult proliferation medium and supplement at a (1:9 ratio), 20 ng/ml Epidermal Growth Factor (EGF) and 1% penstrep. Cell cultures were incubated at 37 °C in 5% CO₂ for 5 to 7 d and every 2 d, half of the medium was changed. This was considered passage 0. NSPCs from passages 2-4 were used for the ex-

periments every 5 or 7 d, cells were passaged by trypsinization and then centrifuged at 1200 g for 5 minutes. The single cells were then seeded at 1×10^5 cells/ml in complete medium.

NSPCs characterization by Immunocytochemistry with Anti-Nestin antibody

NSPCs were seeded at a density of 5000 cells/well in poly-l-ornithine coated plates (SPL) in complete neural stem cell proliferation for 7 days. The coating procedure was performed in a way to let neural stem cells form neurospheres; diluted (1:4) Poly-l-ornithine in PBS was incubated in 96 well plates for only less than an hour in an incubator. After 7 days wells were gently washed twice with PBS and fixed in 1% paraformaldehyde for 20 minutes. Fixed cells are then permeabilized in 0.1% TritonX-100 for 5 min for nestin (a cytoplasmic marker). Nonspecific antibody binding sites were blocked by incubating with 5% Normal Goat Serum and 1% Bovine Serum Albumin in PBS for 1 h. Cells are rinsed twice with PBS and labeled with mouse nestin monoclonal antibody (1:200) in PBS containing 10% BSA at 4 °C overnight. Before staining the nuclei with 7-Aminoactinomycin D (7-AAD) nuclear stain for 1 min, wells are rinsed cautiously with PBS and then incubated with FITC-conjugated anti-mouse nestin antibody (1:600) for 2 h at room temperature.

Immunofluorescent-labeled cells were visualized with Nikon Eclipse TS100 microscope coupled with a True Chrome Metrics camera. Images were taken at 10X magnification from 3 random areas in each well (n=3 for each condition). Images were processed using Photoshop CC 2016 and the intensity of each image was analyzed using ImageJ software.

RNA extraction and Real-time PCR

The NSPCs were plated at a density of 2×10^5 Cells per 24 well plates coated with Poly-l-ornithine in complete neural stem cells media. Total RNA was extracted from cultured cells using RNXplus reagent (Cinnagen) according to the manufacturer's instructions.

Total RNA (1µM) was reverse transcribed into cDNA using Prime Script II First Strand cDNA synthesis Kit (TaKaRa), and 0.1% of cDNA mixture was used as polymerase chain reaction (PCR) template. Primers are shown in Table 1. The reaction was performed using a SYBR Green PCR Master Mix Kit (Yektataghiz azama) in a Rotor-gene Q (Qiagen) with an initial denaturati-

on step at 95 °C for 30 sec, following 45 cycles. Each cycle transitioned between 3 steps of 95 °C for 5 sec, 60 °C for 30 sec and an extension step of 72 °C for 30 sec. Beta Actin was employed as the housekeeping gene to account for sample variability. Relative gene expression is represented as Fold change ($2^{-\Delta\Delta Ct}$).

Table 1: Designed primers for the study

<i>Gene Name</i>	<i>Forward Primer 5' →3'</i>	<i>Reverse Primer 5' →3'</i>
<i>EDNRB</i>	TCGGACTACAAAGGAAAGCC	TGAACAGCCACCAATCTT
<i>GPR37L1</i>	GTTTGCTGTGGGTATCGTTGG	AGAGACTGAAGGTTGTGACT
<i>PDGFRalpha</i>	GTTGCCITTACGACTCCAGAT	TCACAGCCACCTTCATTACA
<i>CNPase</i>	CTCTACTTTGGCTGGTTTCT	TTCTCCTTGGGTTTCATCTCC
<i>GFAP</i>	GAGACAGAGGAGTGGTATCGG	GCTTCGTGCTTGGCTTGG
<i>Actin Beta</i>	GCAACACGCAGCCAC	CGCAGGGATATCGTCATCCA

Software

For fluorescence intensity analysis and Percentage of antibody, positive cells calculation Image J software was used. The total number of cells and antibody-stained cells were counted manually and automatically by Image J software. For the neurosphere assay (estimating the diameter of the Spheres) Infinity Analyze version 4.6 was used. For primer Design Primer-BLAST and Gene runner 6.5.51 was used. Rotor-Gene Q software, ver. 2.3.1 was used to visualize and partially analyze the Real-time PCR results. Raw data were analyzed in Excel 2014.

Statistical Analysis

All experiments were conducted at least in triplicate (n=3). Data were analyzed using Graphpad prim software (ver. 6.0); Data in the figures are expressed as mean ± SEM. Two-way ANOVA followed by Sidak multiple comparison post hoc was performed to compare differences among multiple treatments. Independent samples t-test was performed to compare differences between two conditions. For all experiments significance was defined as P-value<0.05.

Results

The 14 most highly expressed GPCRs in OPCs compared to Oligodendrocytes

In this study, we analyzed the gene expression profiles of 5 different cells. The comparison of gene expression showed a high resemblance in the expression pattern of Gpr17, EDNRB, Gpr56, Gpr19 and GPR37L1 as indicated in Fig. 1. However, EDNRB and GPR37L1 expression patterns are more alike, both being upregulated in OPCs and astrocytes and lower expression in newly myelinating oligodendrocytes. Whereas, their expression in myelinating oligodendrocytes compared to OPCs is merely unnoticeable. Whether GPR37L1 shares a similar function with EDNRB on oligodendrocytes differentiation is quite an interesting dilemma (13, 14). The expression of Chrm1, Chrm2, Hrh1 and P2ry1 was not significant. Gpr37 and Gpr62 have the same expression pattern too but it was not significant to be discussed.




Fig. 1: Comparison of GPCRs gene expression profiles in astrocyte, neuron, OPC, newly formed OL, myelinating OL cells

Primary culture of Nestin-positive NSPCs and further passaging of these cells

Primary NSPCs culture formed neurospheres of > 200 μ m in diameter (P0) after 7 d of culture. The expression of Nestin decreased (data not shown) and cell culture time was shortened to ~ 5 d in the following passages (Fig. 2). The percentage of PDGFR-alpha mRNA expression didn't show a significant increase in passage 4 compared to passage 2 of cortical neural stem cells culture, albeit CNPase showed a noticeable fold change expression of 1.66 and GFAP mRNA expression was downregulated by almost 5 fold change (50%). PDGFR-alpha is a marker for oligodendrocyte progenitor cells, CNPase is upregulated in mature pre-myelinating and myelinating oligodendrocyte, expressed along MBP and PLP constituents of myelin sheath. As commonly known GFAP is an astrocyte marker, but is also abundantly expressed in radial glial cell

(which is the progenitor cell giving rise to both OPCs and astroglial cells) (Fig. 2).

Endothelin B Receptor and GPR37L1 receptor relative expression in NSPCs at mRNA level

Endothelin B and GPR37L1 expression exhibited greatly increased expression during further Cortical NSPCs passages (with EDNRB and GPR37L1 gene expressions enhanced by almost 3 and 6 fold change in cortices derived from passage 4 compared to passage 2) as shown in Fig. 2. EDNRB and GPR37L1 expression were explored in NSPCs derived from embryonic cortices compared to ganglionic eminences (both at passage 02) alongside Glial markers (CNPase and PDGFR-alpha) and astrocytic marker GFAP. Both EDNRB and GPR37L1 displayed higher gene expressions in NSPCs derived from cortices compared to ganglionic eminences.




Fig. 2: Left side: Primary culture and further passages of Nestin-positive NSPCs
 Right side: Relative expression of Endothelin B Receptor and GPR37L1 receptor in NSPCs at mRNA level

Discussion

In this study, we presented the possible role of GPCRs in driving remyelination. We conducted gene expression analysis on a RNA-seq dataset of genes expressed in cells derived from mouse nervous system. The expression of GPCRs highly expressed in OPCs compared to oligodendrocytes are presented here. Most of these genes were previously reported to harm remyelination.

Among these GPCRS, expression of EDNRB and GPR37L1 were investigated in vitro as well. Anti-Nestin staining was performed for characterizing NSPCs. Commonly Nestin has been utilized as a biological marker to identify NSCs (15). Cells express nestin early in their life cycle. Nestin expression is down-regulated as the cells

progress down a specific cell lineage to become either neuron or glial cells (16, 17). NSPCs express nestin and further passages of cortical NSPCs show a slight reduction in Nestin expression (data not shown). The expression of Gpr371 and EdnrB was explored at mRNA level using real-time PCR in consecutive passages of cortical NSPCs compared to Ganglionic eminences derived NSPCs. Our finding shows Gpr371 has a similar pattern of expression in mice compared to EdnrB.

Developmentally, oligodendrocytes arise from OPCs (18, 19). OPCs themselves arise from sub-ventricular cells in the brain and spinal cord. A myriad of different permissive and inhibitory factors orchestrate the differentiation of oligodendrocytes. Several Inhibitory factors are expressed by axons to usher myelination and diffe-

rentiation of OPCs. Induction of remyelination can be addressed by activation of endogenous OPCs present around demyelinated lesions (2, 3, 20, 21). Our premise was that GPCRs highly expressed in OPCs compared to oligodendrocytes cast an inhibitory effect on oligodendrocyte differentiation.

The most highly expressed GPCR genes in OPCs compared to mature oligodendrocytes were *Gpr3711*, *Ednrb*, *Gpr17*, *Gpr37* and *Gpr56*. *Ednrb*, *Gpr17* and *Gpr37* roles have all been investigated in the context of remyelination. *Ednrb* Regulates the Rate of Oligodendrocyte Regeneration during Remyelination. Other GPCRs such as *Chrm1*, *Chrm2* and *Chrna4* receptors belong to the family of muscarinic and cholinergic receptors and they all demonstrate a significant and mostly impermissible role in oligodendrocyte differentiation and remyelination.

GPR17 is a P2Y purinergic GPCR affecting oligodendrocyte differentiation and myelination. *GPR17* cast a negative effect on this phenomenon. The absence of *Gpr17* enhances remyelination and the activation of *Erk1/2* pathway following *Gpr17* down-regulations corroborate this finding (22, 23). An article released in 2009 portrayed the role of *Gpr17* in remyelination, downregulated in *Olig1*-null mice(24). Recently identification of a non-specific antagonist called pranlukast accelerated myelination following toxin-mediated demyelination (25). Endothelin B receptor was recognized as a potential inhibitory drug target that works in a paracrine and autocrine way to inhibit OPCs differentiation. *ETBR* is expressed on both astrocytes and OPCs(26). Coupling of *ET-1* ligand to this receptor on astrocytes promotes Notch activation in OPCs during remyelination through induction of *Jagged 1* expression in reactive astrocytes (13, 14).

In a microarray-based experiment of isolated cells, *GPR37* was shown to be strongly enriched in mature and pre-mature oligodendrocytes (27). *GPR37* mutant mouse exhibits premature oligodendrocyte differentiation, precocious myelination and hyper myelination (28). The mechanism by which *GPR37* regulates multiple stages of

myelination is elusive. Nevertheless, given its strong enrichment in oligodendrocyte lineage, it can be an interesting drug target. *GPR37* is structurally closely related to endothelin B receptor. *GPR37* is an orphan GPCR distinctly expressed in neuronal and glial cells of the CNS. A negative regulatory effect of *GPR37* was manifested on oligodendrocyte differentiation and myelination (29-31). *GPR37* and *Gpr3711* act as parkin substrates. They are expressed in different CNS areas. The absence of these receptors caused an increase in *ERK1/2* phosphorylation in both cultured oligodendrocytes and leads to decreasing myelin growth (29, 32). Moreover, lacking *GPR37* showed changes in the expression of oligodendroglial proteins such as myelin associated glycoprotein (*MAG*) (33). A highly desirable property of a druggable target is its tissue or cell-type specific expression, reducing the concern over unwanted effects. *GPR37L1* is an orphan GPCR exclusively expressed in the nervous system and are known to be expressed on both neurons and glial cells (30). Another closely related *GPR37L1* is called *GPR37* or also known as parkin associated endothelin-like receptor or “*Pael-R*”. the suggested cognate ligand for these two receptors is prosaposin which is still under investigation. Prosaposin and prosaptide have been numerously reported to exert neuroprotective and oligoprotective effects. Through a bioinformatics approach, several surrogate ligands were proposed to inhibit *GPR3711*, one of them is an orexin 2 receptor antagonist called *JNJ10397049* (34).

Conclusion

The investigation of the most highly expressed GPCRs in OPCs compared to oligodendrocyte in silico and in vitro presents the significant role of GPCRs in remyelination induction. Among the 14 GPCRs mentioned in this study, *GPR37L1* is a potential remyelinating drug target and is suggested for further studies. Other GPCRs presented in this study (*Gpr56*, *Gpr62*, *Gpr19*, *Gpr162* and *Hrh1*) have a probable role in remyelination

induction as well and are presented for further analysis and experimentation in vitro and in vivo.

Journalism Ethics considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgements

We would like to thank Dr. Zahra Zeraatpishe for her help to carry out this study and the personnel at the Animal laboratory of SUMS university. This work was financially supported by the grant number 14482 from Shiraz University of Medical Sciences, Shiraz, Iran.

Conflict of interest

The authors declare that there is no conflict of interest.

References

1. Franklin RJ, Ffrench-Constant C (2008). Remyelination in the CNS: from biology to therapy. *Nat Rev Neurosci*, 9(11):839-55.
2. Cohen-Adad J, El Mendili MM, Lehericy S, et al (2011). Demyelination and degeneration in the injured human spinal cord detected with diffusion and magnetization transfer MRI. *Neuroimage*, 55(3):1024-33.
3. Geurts JJ, Bo L, Roosendaal D, et al (2007). Extensive hippocampal demyelination in multiple sclerosis. *J Neuropathol Exp Neurol*, 66(9):819-827.
4. Franklin RJ, Ffrench-Constant C, Edgar JM, Smith KJ (2012). Neuroprotection and repair in multiple sclerosis. *Nat Rev Neurol*, 8(11):624-34.
5. Medina-Rodriguez EM, Bribian A, Boyd A, et al (2017). Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. *Sci Rep*, 7:43545.
6. Hanson MA, Stevens RC (2009). Discovery of new GPCR biology: one receptor structure at a time. *Structure*, 17(1):8-14.
7. Najm FJ, Madhavan M, Zaremba A, et al (2015). Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. *Nature*, 522(7555):216-20.
8. Deshmukh VA, Tardif V, Lyssiotis CA, et al (2013). A regenerative approach to the treatment of multiple sclerosis. *Nature*, 502:327-332.
9. Huang da W, Sherman BT, Lempicki RA (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc*, 4(1):44-57.
10. Mi H, Muruganujan A, Casagrande JT, Thomas PD (2013). Large-scale gene function analysis with the PANTHER classification system. *Nat Protoc*, 8(8):1551-66.
11. Neves MM, Bobes-Limenes P, Perez-Junquera A, et al (2016). Miniaturized analytical instrumentation for electrochemiluminescence assays: a spectrometer and a photodiode-based device. *Anal Bioanal Chem*, 408:7121-7.
12. Strober W (2001). Trypan Blue Exclusion Test of Cell Viability. *Curr Protoc Immunol*, Appendix 3:Appendix 3B.
13. Hammond TR, Gadea A, Dupree J, et al (2014). Astrocyte-derived endothelin-1 inhibits remyelination through notch activation. *Neuron*, 81(3):588-602.
14. Hammond TR, McEllin B, Morton PD, et al (2015). Endothelin-B Receptor Activation in Astrocytes Regulates the Rate of Oligodendrocyte Regeneration during Remyelination. *Cell Rep*, 13(10):2090-7.
15. Sun T, Wang XJ, Xie SS, et al (2011). A comparison of proliferative capacity and passaging potential between neural stem and progenitor cells in adherent and neurosphere cultures. *Int J Dev Neurosci*, 29(7):723-31.
16. Ernst C, Christie BR (2005). Nestin-expressing cells and their relationship to mitotically active cells in the subventricular zones of the adult rat. *Eur J Neurosci*, 22(12):3059-66.
17. Sunabori T, Tokunaga A, Nagai T (2008). Cell-cycle-specific nestin expression coordinates with morphological changes in embryonic cortical neural progenitors. *J Cell Sci*, 121(Pt 8):1204-12.

18. Goldman SA, Kuypers NJ (2015). How to make an oligodendrocyte. *Development*, 142(23):3983-95.
19. Michalski JP, Kothary R (2015). Oligodendrocytes in a Nutshell. *Front Cell Neurosci*, 9:340.
20. Lassmann H, van Horssen J (2011). The molecular basis of neurodegeneration in multiple sclerosis. *FEBS Lett*, 585(23):3715-23.
21. Mitew S, Kirkcaldie MT, Halliday GM, et al (2010). Focal demyelination in Alzheimer's disease and transgenic mouse models. *Acta Neuropathol*, 119(5):567-77.
22. Boda E, Vigano F, Rosa P, et al (2011). The GPR17 receptor in NG2 expressing cells: focus on in vivo cell maturation and participation in acute trauma and chronic damage. *Glia*, 59(12):1958-73.
23. Lu C, Dong L, Zhou H, et al (2018). G-Protein-Coupled Receptor Gpr17 Regulates Oligodendrocyte Differentiation in Response to Lysolecithin-Induced Demyelination. *Sci Rep*, 8(1):4502.
24. Chen Y, Wu H, Wang S, et al (2009). The oligodendrocyte-specific G protein-coupled receptor GPR17 is a cell-intrinsic timer of myelination. *Nat Neurosci*, 12(11):1398-406.
25. Hennen S, Wang H, Peters L, et al (2013). Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist. *Sci Signal*, 6(298):ra93.
26. Guo Y, Chung SK, Siu CW, et al (2014). Endothelin-1 overexpression exacerbate experimental allergic encephalomyelitis. *J Neuroimmunol*, 276(1-2):64-70.
27. Yang W, Xiao L, Li C, et al (2015). TIP30 inhibits oligodendrocyte precursor cell differentiation via cytoplasmic sequestration of Olig1. *Glia*, 63(4):684-98.
28. Marazziti D, Pietro D, C., Golini E, et al (2013). Precocious cerebellum development and improved motor functions in mice lacking the astrocyte cilium-, patched 1-associated Gpr37l1 receptor. *Proc Natl Acad Sci U S A*, 110(41):16486-16491.
29. Meyer RC, Giddens MM, Schaefer SA, Hall RA (2013). GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin. *Proc Natl Acad Sci U S A*, 110(23):9529-9534.
30. Valdnaire O, Giller T, Breu V, et al (1998). A new family of orphan G protein-coupled receptors predominantly expressed in the brain. *FEBS Lett*, 424(3):193-196.
31. Yang HJ, Vainshtein A, Maik-Rachline G, Peles E (2016). G protein-coupled receptor 37 is a negative regulator of oligodendrocyte differentiation and myelination. *Nat Commun*, 7:10884.
32. Ishii A, Furusho M, Bansal R (2013). Sustained activation of ERK1/2 MAPK in oligodendrocytes and schwann cells enhances myelin growth and stimulates oligodendrocyte progenitor expansion. *J Neurosci*, 33(1):175-186.
33. Alavi MS, Karimi G, Roohbakhsh A (2019). The role of orphan G protein-coupled receptors in the pathophysiology of multiple sclerosis: A review. *Life Sci*, 224:33-40.
34. Ngo T, Ilatovskiy AV, Stewart AG, et al (2017). Orphan receptor ligand discovery by pickpocketing pharmacological neighbors. *Nat Chem Biol*, 13(2):235-242.